Holen Sie sich die Stockscreener-App
6.42
3.38%
0.21
Handel nachbörslich:
6.54
0.12
+1.87%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NEO?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$6.21
Offen:
$6.25
24-Stunden-Volumen:
2.12M
Relative Volume:
1.00
Marktkapitalisierung:
$826.22M
Einnahmen:
$628.25M
Nettoeinkommen (Verlust:
$-78.55M
KGV:
-10.35
EPS:
-0.62
Netto-Cashflow:
$-29.73M
1W Leistung:
-6.96%
1M Leistung:
-8.29%
6M Leistung:
-55.72%
1J Leistung:
-56.62%
1-Tages-Spanne:
$6.23
$6.56
1-Wochen-Bereich:
$6.20
$7.065
52-Wochen-Spanne:
$6.08
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Firmenname
Neogenomics Inc
Sektor
Branche
Telefon
(239) 768-0600
Adresse
9490 NEOGENOMICS WAY, FORT MYERS, FL
Vergleichen Sie NEO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
6.42 | 887.99M | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
427.62 | 157.79B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.91 | 138.02B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
532.00 | 42.36B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
116.19 | 32.08B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
187.38 | 27.28B | 15.50B | 1.33B | 2.16B | 7.34 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-15 | Eingeleitet | Guggenheim | Neutral |
| 2025-04-30 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-12-10 | Eingeleitet | Jefferies | Buy |
| 2024-05-01 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-08-21 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-02-24 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-02-01 | Hochstufung | Needham | Hold → Buy |
| 2022-08-26 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-22 | Herabstufung | Needham | Buy → Hold |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-03-29 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-29 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | Fortgesetzt | Stephens | Overweight |
| 2021-12-16 | Eingeleitet | Cowen | Outperform |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-02-25 | Fortgesetzt | Needham | Buy |
| 2021-02-25 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-12-11 | Fortgesetzt | BTIG Research | Buy |
| 2020-10-28 | Bestätigt | Needham | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-28 | Eingeleitet | Guggenheim | Buy |
| 2020-07-29 | Bestätigt | Needham | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Buy |
| 2020-04-21 | Fortgesetzt | Stephens | Overweight |
| 2020-03-02 | Fortgesetzt | Craig Hallum | Buy |
| 2020-02-28 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-05-01 | Bestätigt | Needham | Buy |
| 2019-03-29 | Bestätigt | Needham | Buy |
| 2019-01-03 | Eingeleitet | Needham | Buy |
| 2018-10-24 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | Eingeleitet | Leerink Partners | Outperform |
| 2018-05-02 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2017-08-24 | Eingeleitet | Gabelli & Co | Buy |
| 2016-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Neogenomics Inc Aktie (NEO) Neueste Nachrichten
Is NeoGenomics Inc. a good long term investmentFree Expert Stock Watchlist - jammulinksnews.com
What drives NeoGenomics Inc. stock priceRapid-fire capital growth - jammulinksnews.com
NeoGenomics (NEO) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
NeoGenomics Inc. Stock Analysis and ForecastDynamic investment opportunities - jammulinksnews.com
What analysts say about NeoGenomics Inc. stockUnmatched profit potential - Autocar Professional
Personalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy - Nature
Neogenomics Shares Plunge 7.14% Amid Earnings Woes - AInvest
Moderna, Lantheus, Centene, AMN Healthcare Services, and NeoGenomics Shares Plummet, What You Need To Know - Yahoo Finance
Pathological Examination Market Gaining Momentum in Cancer - openPR.com
NeoGenomics (NASDAQ:NEO investor five-year losses grow to 81% as the stock sheds US$71m this past week - simplywall.st
Why NeoGenomics Inc. stock attracts strong analyst attention200 Percent Profit Outlook - beatles.ru
Q1 Earnings Highlights: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Testing & Diagnostics Services Stocks - Yahoo Finance
NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO - ACCESS Newswire
NEO Stock Price and Chart — NASDAQ:NEO - TradingView
NeoGenomics, RadNet, Pediatrix Medical Group, Penumbra, and Neogen Shares Plummet, What You Need To Know - Yahoo Finance
NeoGenomics Announces Grand Opening of New Pharma Services Laboratory in Singapore - ACCESS Newswire
Press Release: NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025 - 富途牛牛
NeoGenomics (NEO): A Contrarian Play on Turnaround and Undervaluation - AInvest
The past five years for NeoGenomics (NASDAQ:NEO) investors has not been profitable - Yahoo Finance
NeoGenomics Announces Chief Executive Officer Appointment - ACCESS Newswire
Here’s Why NeoGenomics (NEO) Sold Off in Q1 - Insider Monkey
NeoGenomics To Participate In Fireside Chat At Stephens 21st Annual Investment Conference - ACCESS Newswire
NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025 - Bluefield Daily Telegraph
NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care - The Joplin Globe
5 Insightful Analyst Questions From NeoGenomics’s Q1 Earnings Call - Yahoo Finance
NeoGenomics' Market Cap Drops To US$954m Leaving Insiders With Losses - simplywall.st
NeoGenomics Requests to Dismiss Class Action Filed by Investors - TradingView
NeoGenomics drops as sequential revenue decline leads to Q1 miss - MSN
NeoGenomics Schedules its First Quarter 2021 Earnings Release for May 5, 2021 - ACCESS Newswire
Investor Calendar Invites You to the NeoGenomics Fourth Quarter and Fiscal Year 2015 Earnings Conference Call and Webcast Live on Tuesday March 1, 2016 - ACCESS Newswire
NeoGenomics at William Blair Conference: Strategic Growth and Innovation By Investing.com - Investing.com South Africa
NeoGenomics at William Blair Conference: Strategic Growth and Innovation - Investing.com Australia
Where are the Opportunities in (NEO) - news.stocktradersdaily.com
Cancer Tumor Profiling Market Rises with Demand - openPR.com
Liquid Biopsy Market for Cancer Detection, cfDNA & CTC Analysis | - openPR.com
Fort Myers-based NeoGenomics to unveil new cancer diagnostics at ASCO 2025 - Gulfshore Business
NeoGenomics unveils new oncology diagnostics at ASCO 2025 By Investing.com - Investing.com South Africa
Neogenomics director Kelly buys $38,000 in common stock - Investing.com Australia
Neogenomics director Kelly buys $38,000 in common stock By Investing.com - Investing.com Nigeria
NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025 - BioSpace
Finanzdaten der Neogenomics Inc-Aktie (NEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.06%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):